Bio Medica Laboratories Limited
Minimum investment
Bidding date
21 May - 25 May 2026
Price range
₹132 - ₹139
Minimum quantity
2,000
Minimum investment
₹1,32,000
Issue size
₹52 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Total Issue Size:
₹52.43 Crore
Fresh Issue: 90% (₹47.19 Cr)
OFS: 10% (₹5.24 Cr)
Fresh Issue – ₹47.19 Crore
Offer for Sale – ₹5.24 Crore
Before Issue: 99.99%
After Issue: 69.99%
Lock-in / Stabilization | Timeline |
|---|---|
Minimum Promoter Contribution Shares | 3 Years |
Promoter Holding in Excess of Minimum Contribution (50%) | 1 Year |
Remaining Promoter Holding in Excess of Minimum Contribution (50%) | 2 Years |
Pre-Issue Shareholding (Other Locked-in Shares) | 1 Year |
Note: Retail IPO investors have no lock-in and can sell shares from the listing day.
Bio Medica Laboratories Ltd. was incorporated in August 2015 and is engaged in the manufacturing of pharmaceutical parenteral formulations. The company produces a wide range of ethical drugs, generic medicines, and over-the-counter (OTC) products in both liquid injectable and dry powder injectable forms. Its products cater to human as well as veterinary healthcare requirements. The company offers 58 liquid injectable products and 15 dry powder injectable products. Bio Medica Laboratories follows a B2B contract manufacturing model, where it develops and manufactures formulations as per the requirements and specifications of pharmaceutical companies. The company operates two manufacturing facilities located in Indore, Madhya Pradesh. These facilities are certified with Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications issued by the Food & Drugs Administration, Madhya Pradesh. Bio Medica Laboratories has shown strong financial growth over the last few years. The company reported total income of Rs. 38.33 crore and PAT of Rs. 9.79 crore for FY2025. As of November 2025, the company reported assets worth Rs. 65.17 crore with EBITDA of Rs. 13.45 crore.
Diversified Product Portfolio: Bio Medica Laboratories Ltd. offers a wide range of pharmaceutical injectable products, including liquid injectables and dry powder injectables for both human and veterinary healthcare markets. This diversified portfolio helps the company cater to multiple customer segments.
Established B2B Business Model: The company operates on a contract manufacturing B2B model, developing and manufacturing products according to client requirements. This business model supports stable client relationships and recurring business opportunities.
Certified Manufacturing Facilities: Bio Medica Laboratories has GMP and GLP certified manufacturing facilities located in Indore, Madhya Pradesh. These certifications reflect the company’s focus on maintaining product quality and regulatory standards.
Strong Financial Growth: The company has reported strong growth in revenue and profitability over the last few years. Profit After Tax increased significantly from Rs. 0.33 crore in FY2023 to Rs. 9.79 crore in FY2025, indicating improving operational efficiency.
Experienced Management Team: The company is led by experienced promoters, Mr. Mukesh Mehta and Mr. Pradeep Mehta, who possess industry expertise and operational experience in the pharmaceutical manufacturing sector.
Dependency on Contract Manufacturing: The company primarily operates through contract manufacturing arrangements. Any slowdown in orders from client companies may impact revenue growth and business operations.
High Borrowings: Bio Medica Laboratories has comparatively high borrowings, which may impact profitability and cash flows if debt levels continue to rise in the future.
Concentration Risk: The company currently operates mainly from two manufacturing facilities located in Indore, Madhya Pradesh. Any disruption at these facilities could affect production and business continuity.
Regulatory Risks: The pharmaceutical industry is highly regulated and requires strict compliance with quality and safety standards. Any failure to comply with regulatory requirements may impact the company’s operations.
SME Listing Risk: As the IPO is proposed to be listed on the NSE SME platform, investors may face higher price volatility and lower liquidity compared to mainboard-listed companies.
28.63 Cr.
Nov'25
8.66 Cr.
Nov'25
13.45 Cr.
Nov'25
46 investors voted
Active IPOs | |
|---|---|
Company name | Bid starts |
Nfp Sampoorna Foods | 18-05-2026 |
Teamtech Formwork Solutions | 19-05-2026 |
Bio Medica Laboratories | 21-05-2026 |
Q Line Biotech | 21-05-2026 |
